Health and Healthcare

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

185 Articles

Trey Thoelcke | Feb 26, 2016 at 11:56 AM EST

Big Pharma Matchup: Valeant vs Gilead

Here are two big biopharmas, both with multibillion dollar portfolios and both of which have lost a combined $113 billion…

Douglas A. McIntyre | Feb 25, 2016 at 6:48 AM EST

CEOs Who Have to Go in 2016

Shareholders put their trust in the chief executive officer to direct the company to better fortunes. At some point, however,…

Chris Lange | Dec 28, 2015 at 11:40 AM EST

Valeant CEO Takes Temporary Leave on Health Scare

Valeant Pharmaceuticals watched its shares move lower in Monday’s trading session on a health scare from one of its top…

Trey Thoelcke | Dec 18, 2015 at 7:10 AM EST

4 Top Biotech Stocks for 2016

Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better…

Douglas A. McIntyre | Nov 23, 2015 at 10:28 AM EST

10 Stocks to Pick Up in December

Here are 10 stocks that could outperform the index funds from now to early February.

Chris Lange | Nov 21, 2015 at 10:25 AM EST

6 BioHealth Movers That Now Cannot Be Ignored

24/7 Wall St. examines Valeant Pharmaceuticals and other biotech stocks with incredible gains or losses over the course of the…

Lee Jackson | Nov 11, 2015 at 10:55 AM EST

Jefferies Has 4 Very Bold Value Calls This Week

All these top value picks at Jefferies have some degree of either headline risk or just headline overhang, but the…

Chris Lange | Nov 7, 2015 at 9:25 AM EST

5 BioPharma Movers That Cannot Be Ignored

Last week, a few biotech companies made absolutely massive runs, while others had serious falls.

Paul Ausick | Nov 5, 2015 at 4:04 PM EST

The 52-Week Low Club for Thursday

November 5, 2015: Here are four stocks trading with heavy volume among 92 equities making new 52-week lows today. Qualcomm…

Chris Lange | Oct 31, 2015 at 10:10 AM EDT

6 BioPharma Movers That Cannot Be Ignored

Last week, a few biotech companies made absolutely massive runs, and some had serious falls.

Jon C. Ogg | Oct 30, 2015 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: DreamWorks, First Solar, NVIDIA, SolarCity, Valeant, YRC Worldwide and More

Friday's top analyst upgrades, downgrades and initiations include DreamWorks Animation, First Solar, NVIDIA, SolarCity, Valeant Pharmaceuticals and YRC Worldwide.

Jon C. Ogg | Oct 27, 2015 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: BioDelivery, Merrimack, Silver Wheaton, Valeant, Weatherford and More

Tuesday's top analyst upgrades, downgrades and initiations include BioDelivery Sciences, Merrimack Pharmaceuticals, Silver Wheaton, Valeant Pharmaceuticals and Weatherford International.

Chris Lange | Oct 24, 2015 at 9:40 AM EDT

8 BioPharma Movers That Cannot Be Ignored

These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the…

Paul Ausick | Oct 21, 2015 at 4:04 PM EDT

The 52-Week Low Club for Wednesday

October 21, 2015: Here are four stocks trading with heavy volume among 94 equities making new 52-week lows today. Valeant…

Jon C. Ogg | Oct 21, 2015 at 12:50 PM EDT

6 Key Analyst Downgrades From Wednesday That Cannot Be Overlooked

Several key analyst downgrades on Wednesday were too big to overlook. Some moves may seem obvious, but they may seal…

1 … 7 8 9 10 11 … 13

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

Big Pharma Matchup: Valeant vs Gilead

CEOs Who Have to Go in 2016

Valeant CEO Takes Temporary Leave on Health Scare

4 Top Biotech Stocks for 2016

10 Stocks to Pick Up in December

6 BioHealth Movers That Now Cannot Be Ignored

Jefferies Has 4 Very Bold Value Calls This Week

5 BioPharma Movers That Cannot Be Ignored

The 52-Week Low Club for Thursday

6 BioPharma Movers That Cannot Be Ignored

Top Analyst Upgrades and Downgrades: DreamWorks, First Solar, NVIDIA, SolarCity, Valeant, YRC Worldwide and More

Top Analyst Upgrades and Downgrades: BioDelivery, Merrimack, Silver Wheaton, Valeant, Weatherford and More

8 BioPharma Movers That Cannot Be Ignored

The 52-Week Low Club for Wednesday

6 Key Analyst Downgrades From Wednesday That Cannot Be Overlooked

Skip ARKK’s Moonshots: This Fund Owns the AI Software Winners for 0.45%

NVIDA Vs. Tesla: Tesla Jumps as It Finally Fulfills Decade-Old Promise So Buy Nvidia Instead

The Dividend Growth Plan That Leaves High-Yield Stocks Behind

The Dividend Growth Plan That Leaves High-Yield Stocks Behind

"Bro, 3 Years and the Finances Are Separate?": Caleb Hammer Confronts Married Couple With 4 Kids and a Past-Due Mortgage

Skip ARKK’s Moonshots: This Fund Owns the AI Software Winners for 0.45%

NVIDA Vs. Tesla: Tesla Jumps as It Finally Fulfills Decade-Old Promise So Buy Nvidia Instead

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

Big Pharma Matchup: Valeant vs Gilead

CEOs Who Have to Go in 2016

Valeant CEO Takes Temporary Leave on Health Scare

4 Top Biotech Stocks for 2016

10 Stocks to Pick Up in December

6 BioHealth Movers That Now Cannot Be Ignored

Jefferies Has 4 Very Bold Value Calls This Week

5 BioPharma Movers That Cannot Be Ignored

The 52-Week Low Club for Thursday

6 BioPharma Movers That Cannot Be Ignored

Top Analyst Upgrades and Downgrades: DreamWorks, First Solar, NVIDIA, SolarCity, Valeant, YRC Worldwide and More

Top Analyst Upgrades and Downgrades: BioDelivery, Merrimack, Silver Wheaton, Valeant, Weatherford and More

8 BioPharma Movers That Cannot Be Ignored

The 52-Week Low Club for Wednesday

6 Key Analyst Downgrades From Wednesday That Cannot Be Overlooked

Skip ARKK’s Moonshots: This Fund Owns the AI Software Winners for 0.45%

NVIDA Vs. Tesla: Tesla Jumps as It Finally Fulfills Decade-Old Promise So Buy Nvidia Instead

The Dividend Growth Plan That Leaves High-Yield Stocks Behind

Featured Reads

The Dividend Growth Plan That Leaves High-Yield Stocks Behind

"Bro, 3 Years and the Finances Are Separate?": Caleb Hammer Confronts Married Couple With 4 Kids and a Past-Due Mortgage